I have been thinking about Black Friday and holiday
I have been thinking about Black Friday and holiday wishes… I know what I want and if things work out we should be able to attain the beginnings of my wish this coming year. If you’re listening Santa here is what I want…
The 200 million shares opens the possibilities of not only securing our financing of our trials and purchase of Leronlimab from Samsung. If the next few catalysts do what we hope they do in securing a accent to a much higher stock price. Then the possibilities run rampant with my wish. More stock price value gives us independence to grow our company quickly with larger purchases of Leronlimab. To give us that jolt of not having to wait for the revenue to come before we repurchase again and again. Once revenue starts making a large purchase is priority to kick starting this company in the right direction. Having the funds to do it before waiting 90 days for revenue to show as companies usually pay within that time period. Could be a real slow down. It’s a big opportunity to be able to finance a quicker purchase and grow grow grow…
If you’re wondering what my wish is and you know from my past posts. It will be no surprise. My wish is we become our own pharmaceutical company and grow grow grow. This coming year is our year for a few approvals and after two approvals my dream becomes true I believe. Give us two approvals in Cancer and a few Covid indications and throw in a late BLA approval in HIV and my dream of my wish very much becomes true. Why is that you say? Because after a couple of quick approvals this year… nobody will be able to afford to buy us out. We will grow into our own big Pharma and grow into a top 10 in the world if not top 3 on so many Block Buster Indications we have defined. We don’t need any partners in any indication either. Let me say that again… we don’t need any partners!!!
This coming year is so exciting and yet we wait patiently as we have for the past few years. The difference is… we know trial results that are not just good but very good. This is a huge difference in waiting for a BLA and knowing we met the primary end point but just can’t get the handle on filing the BLA. A much approved position to be in.
We have taken the science of Leronlimab to new levels with better defined trials that have shown us proven results in Cancer mTNBC, Nash, HIV, Covid and even solid tumor cancers. Maybe even all cancers as we become an oncology company. We have many more autoimmune indications to look forward to also.
Our recent trials results can’t be denied and now just need to be explored a tiny bit more before we are well on our way. We hope this year produces BTD’s and BLA’s and a few quick EUA’s. Every indication trialed has been fast tracked process approved or will be including the Covid EUA temporary approval processes.
If you haven’t paid attention to the possibilities of what fast tracked means or says about our molecule… it say to me that the FDA recognizes the importance of the results of the molecule and wants to help us get there in approving it for each faster process we apply for. Ground breaking recognition. The 13d and shorts don’t want you to believe we have a good relationship with the FDA but if we did not have a good relationship… would we get all these faster processing approval processes? I don’t think so. So now is the time to believe in what we have and our future in my opinion.
If I am right then not only does my dream become true but we all become very well off with this investment. I believe by years end of 2022 we approach $100/share. That is just the beginning and I believe in a four figure stock price some day and that could be 5 years or maybe a tiny bit longer… but sooner than later when you do the math on each market indication as we seek Block Buster drug approvals on a true platform drug potential.
I know I am thankful to be invested in this miracle molecule. Recognizing the opportunities is just the start of knowing where we are headed. The future is so bright… we all have something to be thankful for this fine holiday.
Happy Holidays to you and yours and a very Happy Thanksgiving. Dream a little… dream of summer houses and boats and RV’s and international travel… this is what I dream about. Yes I am a true optimist and have optimistic opinions of Leronlimab. Live a little and and enjoy the possibilities we have before us… just dream a little!
13
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
The Rise of "Safe Ground" on Prime Video This isn't your typical feel-good story—it’s about grit and the unending fight for 'normalcy' where war left scars. Safe Ground, now streaming on Prime Video, showcases Ryan Hendrickson, a U.S. Army Green Beret whose story takes a sharp turn after stepping on an IED in 2010. The day he almost became just another statistic...
Continue Reading
Global Investment Winds Shift at CIFIT In the thick of a world that's being turned on its head, you've got big shots from 129 countries and 30 international organizations talking shop at the 26th China International Fair for Investment and Trade (CIFIT) in Xiamen. Take your pick from the 48 of the world's top 50 GDP powerhouses rubbing shoulders there—this ain't your...
Continue Reading
Preserving Our Natural Chompers Digging into the details of endodontic care, you realize how it's the unsung hero in the dental world. And let's face it, teeth don't get happier on their own when there's a problem on the inside. Dr. Christopher Joubert, a wiz on the endodontic front, spills the beans over at HelloNation about how essential these practices are in keeping...
Continue Reading
Call it a seismic shift or call it common sense, but ARTiSTORY's recent haul of accolades makes it clear: they're onto something big in the cultural IP game. Receiving four honors at the 26th International Advertising Institute Awards (IAI Awards), including a Gold for their British Library × CHAGEE collaboration, and jumping into License Global's Top 60, they're staking...
Continue Reading
ACE 2: A Thermal Riflescope That Promises More Let’s dive right into the nitty-gritty of Nocpix’s latest move. On September 12, they launched the ACE 2 Series—the next-gen beast of their flagship thermal riflescope lineup. A step up from the original ACE, this series aims to redefine what hunters can expect from a riflescope, introducing three models: ACE 2 S60R,...
Continue Reading
Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...
Continue Reading
Ajman: A Tourism Gem in the Making Swinging into the Arabian Travel Market 2026, Ajman isn't just a footnote in the UAE's tourism playbook anymore, it's gunning for the spotlight. There's a flurry of activity as the Ajman Department of Tourism, Culture and Media rolls up its sleeves to flaunt the emirate's kaleidoscope of attractions to the world's tourism brass. Going...
Continue Reading
Digestive Wellness: The Emerging Opportunity Some days, it feels like everybody's got a gripe about their gut. You nod along at the lunch counter, folks buzzing about digestive this and acid that. But when PureHealth Research pops up with their fancy supplements, well, even the stock market's noisier nonsense starts sounding a bit quieter. They're banking big on the...
Continue Reading
China-Europe Trade Ties Continue to Tighten You ever watch a cargo ship glide into port and think, "There's a piece of the future right there”? Well, that's the scene at Poland’s Gdansk Port, now officially etched into the Silk Road Maritime route. This ain't just a couple of extra boats cutting through choppy waters—it's a great leap forward for a strained global...
Continue Reading
Honoring Tradition and Service The good ol’ U.S. Postal Service is at it again, giving a tip of the hat to a slice of American military heritage. This time, they’re putting out a new stamp to celebrate the 150th anniversary of the U.S. Coast Guard Academy. And you know where they did the honors? Right there on Custom House Pier in New London, Connecticut, a place that...
Continue Reading
Top 5 Most Recently Viewed Articles
Cingulate Inc. Announced Financial Highlights for Q2 2025 Cingulate Inc. (NASDAQ: CING), a prominent biopharmaceutical company focused on innovative ADHD treatments, recently disclosed its financial results for the second quarter of 2025, alongside significant advancements. Central to the company’s activities was the submission of the New Drug Application (NDA) for its...
Continue Reading
Investment Growth Over Five Years Investing wisely can create remarkable returns over time. A case in point is Carvana Co (NASDAQ: CVNA), which has significantly outperformed expectations in recent years. Over the past five years, Carvana has shown an impressive annualized return of 18.46%, surpassing the market by 4.39% each year. Presently, Carvana's market...
Continue Reading
Deko Cocktails Achieves WSWA Best RTD Award Deko Cocktails, a newly launched line of expertly crafted ready-to-serve cocktails, recently secured a prestigious accolade in the beverage alcohol industry. The company was honored with the Best RTD (Ready to Drink) Product of the Year at the Wine & Spirit Wholesalers of America (WSWA) Brand Battle. This annual competition...
Continue Reading
Key Insights on Bouygues SA's Monthly Share and Voting Rights Bouygues SA regularly updates its shareholders about essential metrics, including the total number of shares and the voting rights attached to them. Understanding these details is vital for investors and stakeholders who wish to stay informed of the company's standing in the market. Transparency in Shareholder...
Continue Reading
Oncternal Therapeutics Inc. (ONCT) was in dire straits back then, hitting a notable low of $1.31 amidst a turbulent market that left investors biting their nails. This stock plunge represented a hefty drop of -76.33%, rattling traders who were already on edge over the biopharmaceutical company’s struggle to bring innovative cancer therapies to market. The company's...
Continue Reading